Literature DB >> 9158213

Hypertension in the hemodialysis population: any relation to one-year survival?

M M Salem1, J Bower.   

Abstract

Few studies have quantified the effect of hypertension on survival in the hemodialysis population. We report the effect of hypertension on 1-year survival in 649 hemodialysis patients (89% black). In univariate analysis, hypertension was associated with improved 1-year survival (relative risk [RR], 0.48; P = 0.002 compared with normotensive patients). This effect of hypertension was mostly caused by the associated antihypertensive treatment because untreated hypertensive patients had survival rates equal to normotensive patients (RR, 0.87; P = 0.70). On the other hand, treated hypertensive patients fared better than normotensive patients (RR, 0.41; P = 0.0006). This was also true in multivariate analysis, in which antihypertensive treatment was associated with reduced RR (RR, 0.55; P = 0.02) whereas the level of blood pressure per se was insignificant (RR, 0.99; P = 0.63 per 1 mm Hg increase in predialysis mean arterial pressure). Other factors of significance in multivariate analysis included age (RR, 1.03/y; P = 0.0004), serum albumin (RR, 0.38/g; P = 0.002), and diabetes mellitus (RR, 1.58; P = 0.06). Our study suggests that antihypertensive treatment has a favorable effect on survival in the hemodialysis population irrespective of the level of blood pressure control.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9158213     DOI: 10.1016/s0272-6386(96)90257-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  14 in total

Review 1.  Medical safety in the care of the person with end-stage kidney disease.

Authors:  John V Duronville; Clarissa J Diamantidis
Journal:  Semin Dial       Date:  2018-01-07       Impact factor: 3.455

2.  Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients.

Authors:  J K Inrig; E Z Oddone; V Hasselblad; Barbara Gillespie; U D Patel; D Reddan; R Toto; J Himmelfarb; J F Winchester; J Stivelman; R M Lindsay; L A Szczech
Journal:  Kidney Int       Date:  2007-01-10       Impact factor: 10.612

Review 3.  Current understanding of optimal blood pressure goals in dialysis patients.

Authors:  Paul Light
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

Review 4.  Treatment of hypertension in the hemodialysis patient: beneficial or not?

Authors:  M M Salem
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 5.  Hypertension in hemodialysis patients.

Authors:  M Rahman; M C Smith
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 6.  Blood Pressure and Mortality in Long-Term Hemodialysis-Time to Move Forward.

Authors:  Panagiotis I Georgianos; Rajiv Agarwal
Journal:  Am J Hypertens       Date:  2017-03-01       Impact factor: 2.689

7.  Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study.

Authors:  Y Hayashino; S Fukuhara; T Akiba; T Akizawa; Y Asano; A Saito; J L Bragg-Gresham; S P B Ramirez; F K Port; K Kurokawa
Journal:  Diabetologia       Date:  2007-03-29       Impact factor: 10.122

8.  Weekly averaged blood pressure is more important than a single-point blood pressure measurement in the risk stratification of dialysis patients.

Authors:  Hidekazu Moriya; Machiko Oka; Kyoko Maesato; Tsutomu Mano; Ryota Ikee; Takayasu Ohtake; Shuzo Kobayashi
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 8.237

Review 9.  Assessment and management of hypertension in patients on dialysis.

Authors:  Rajiv Agarwal; Joseph Flynn; Velvie Pogue; Mahboob Rahman; Efrain Reisin; Matthew R Weir
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

Review 10.  Target blood pressure in patients with end-stage renal disease: evidence-based medicine or the emperor's new clothes?

Authors:  Thomas G Pickering
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.